Curanex Pharmaceuticals Inc (CURX) Financials

$4.31

$0.11 (2.62%)

As on 10-Sep-2026 16:00EDT

Market cap

$8 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	0.03	--
Cost of Revenue	0.07	--	--	--	0.02	--
Gross Profit	-0.07	--	--	--	0.00	--
Operating Expenses	10.48	4.24	0.37	0.02	0.02	--
Operating Profit (EBIT)	-10.55	-4.24	-0.37	-0.02	-0.02	--
Other Income	--	--	--	--	--	--
Profit before Tax	-10.47	-4.23	-0.36	-0.02	-0.02	--
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-10.47	-4.23	-0.36	-0.02	-0.02	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	--

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	4.79	11.22	0.50	0.06	0.01	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.18	0.22	--	--	--	--
Current Liabilities	0.10	0.14	0.01	0.01	--	--
Total Liabilities	5.18	11.58	0.52	0.07	0.01	--

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.28	0.35	--	--	--	--
Current Assets	4.79	11.23	0.52	0.07	0.01	--
Total Assets	9.87	11.58	0.52	0.07	0.01	--
Total Debt*	0.28	0.35	--	--	--	--
Net Current Assets	--	11.09	0.50	0.06	0.01	--

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-10.48	-0.56	0.00	0.00	--
Cash Flow from Investing Activities	--	--	--	--	--	--
Cash from Financing Activities	--	15.31	0.63	0.07	0.00	--
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-7.39	-2.98	-0.26	-0.01	--	--
Cash EPS ($)	--	-2.93	-0.26	-0.01	--	--
Adjusted Book Value ($)	--	7.92	0.36	0.04	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-7.40	-0.40	0.00	--	--
Free Cash Flow per Share ($)	--	-7.40	-0.40	0.00	--	--

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-70.02	-128.32	-54.60	--	--
ROE (%)	-130.80	-72.09	-128.32	-54.60	--	--
ROA (%)	-195.12	-69.85	-122.07	-45.39	--	--
EBIT Margin (%)	--	--	--	--	-77.82	--
Net Margin (%)	--	--	--	--	-77.82	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	-1.00	--	--
EBIT Growth (%)	-3,634.70	--	--	4.62	--	--
Net Profit Growth (%)	-2,306.33	-1,068.75	-1,783.04	5.12	--	--
EPS Growth (%)	-2,255.51	-10.44	-17.83	--	--	--
Book Value Growth (%)	1,433.59	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.11	--	--	--	--
Price / Book Value	1.47	0.04	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	--	0.99	--	--	--	--
Close Price ($)	5.30	6.61	--	--	--	--
High Price ($)	183.60	183.60	--	--	--	--
Low Price ($)	5.22	6.44	--	--	--	--
Market Cap ($ Cr)	7.92	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.03	--	--	--	--
Short term debt to equity ratio	0.02	0.01	--	--	--	--
Current Ratio	45.95	81.93	35.54	5.21	--	--
Quick Ratio	45.95	--	--	5.21	--	--
Interest Coverage	-493.63	-493.92	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	50.58	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.